A new technology introduced at Liverpool Heart and Chest Hospital NHS Foundation Trust is enabling specialists to assess lung tissue samples remotely in real time during diagnostic procedures, reportedly helping avoid delays, reduce patient anxiety, and ensure treatment can begin sooner.
Remote rapid on-site evaluation (ROSE) technology permits the analysis of samples while a patient is still undergoing an endobronchial ultrasound, the trust explains, highlighting whether enough tissue has been collected for diagnosis. This, it continues, can prevent the inconvenience of further appointments.
Slides are prepared and stained by the technology, before being sent remotely to pathologists, who can manoeuvre the microscope, view the slides, and offer live feedback on diagnoses, according to LHCH. Emily Hoodless, consultant respiratory physician, points to the benefits for patients in avoiding the discomfort and anxiety of a second procedure, and in finding out a diagnosis “quicker than ever before”.
Emily shares that the new procedure will initially be offered to those at the highest risk of lung cancer. “Avoiding any delays in diagnosis is vital,” she says. “The earlier we can confirm a diagnosis, the sooner any necessary treatment can be initiated, and the sooner we can provide reassurance where cancer is not found. Furthermore, we plan to use this new technology to support future research, helping us to improve care and treatment for patients in the years ahead.”
Funding from the LHCH charity and the Tevir Group on behalf of the Keith Jones Foundation made the trust’s use of the technology possible, it notes.
Also this month, the University Hospitals of Liverpool Group announced its introduction of automated medicine management, supporting an aim for safer and efficient medicines processes. Automated dispensing cabinets will be installed in 48 clinical areas over the next two years at Aintree University Hospital. These will reportedly provide clinicians with information about patients and medications, offering integration with wider hospital medication and IT systems.
Wider trend: Digital diagnostics
Humber and North Yorkshire Collaboration of Acute Providers annual report for 2025/26 has shared achievements across imaging, diagnostics and order comms, with discussion on next steps and the future of acute care in the region. £500k has been secured to support the implementation of digital diagnostics for Humber and North Yorkshire, it shares, and an expression of interest has been completed for the diagnostic digital capacity fund 2026-30, with £24 million of investment requested over the next four years.
Maidstone and Tunbridge Wells NHS Trust has shared plans for outpatient and diagnostic transformation, remote care, and digital innovation in its latest trust strategy to 2031, aiming to reshape the way care is delivered, optimise existing digital systems, and embrace new digital opportunities. The trust looks to position itself as a regional leader in digitally enabled surgical care, expanding triage to test models, diagnostics with clinical decision support, putting in place patient-initiated follow-up, expanding virtual wards and virtual surgical pathways, and ensuring integrated community-based services supported by digital integration.
TidalSense, a Cambridge-based AI respiratory diagnostics company, has shared that it has successfully raised £16 million in funding to accelerate the European and US commercialisation of its AI diagnostic device for COPD. This latest announcement means that TidalSense has now raised £34 million to date, including a reported £9 million in grants from UK bodies such as NIHR, Innovate UK, and Asthma-Lung UK. The company states that its N-Tidal Diagnose software, CE marked under EU MDR (Class IIa) for COPD, “uses AI-analysed tidal breathing — rather than the forced exhalation required by spirometry — to deliver a fast, non-invasive diagnosis of COPD in under five minutes, without specialist training or hospital-grade equipment”.





